- Home
- ALNY vs TRV Comparison
ALNY vs TRV Comparison
Compare ALNY & TRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALNY
- TRV
- Stock Information
- Founded
- ALNY 2002
- TRV 1853
- Country
- ALNY United States
- TRV United States
- Employees
- ALNY N/A
- TRV N/A
- Industry
- ALNY Biotechnology: Pharmaceutical Preparations
- TRV Property-Casualty Insurers
- Sector
- ALNY Health Care
- TRV Finance
- Exchange
- ALNY Nasdaq
- TRV Nasdaq
- Market Cap
- ALNY 59.2B
- TRV 60.1B
- IPO Year
- ALNY 2004
- TRV 1996
- Fundamental
- Price
- ALNY $459.28
- TRV $274.23
- Analyst Decision
- ALNY Strong Buy
- TRV Hold
- Analyst Count
- ALNY 27
- TRV 14
- Target Price
- ALNY $420.73
- TRV $283.93
- AVG Volume (30 Days)
- ALNY 1.1M
- TRV 1.2M
- Earning Date
- ALNY 10-30-2025
- TRV 10-16-2025
- Dividend Yield
- ALNY N/A
- TRV 1.60%
- EPS Growth
- ALNY N/A
- TRV 43.22
- EPS
- ALNY N/A
- TRV 22.64
- Revenue
- ALNY $2,461,963,000.00
- TRV $47,838,000,000.00
- Revenue This Year
- ALNY $58.97
- TRV N/A
- Revenue Next Year
- ALNY $38.81
- TRV $4.18
- P/E Ratio
- ALNY N/A
- TRV $12.12
- Revenue Growth
- ALNY 5.01
- TRV 8.54
- 52 Week Low
- ALNY $205.87
- TRV $224.62
- 52 Week High
- ALNY $469.81
- TRV $280.70
- Technical
- Relative Strength Index (RSI)
- ALNY 70.91
- TRV 55.89
- Support Level
- ALNY $444.66
- TRV $271.34
- Resistance Level
- ALNY $458.30
- TRV $280.70
- Average True Range (ATR)
- ALNY 10.97
- TRV 4.05
- MACD
- ALNY -3.77
- TRV 0.01
- Stochastic Oscillator
- ALNY 71.78
- TRV 43.50
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
About TRV The Travelers Companies Inc.
Travelers offers a broad product range and participates in both commercial and personal insurance lines. Its commercial operations offer a variety of coverage types for companies of any size but concentrate on serving midsize businesses. Its personal lines are roughly evenly split between auto and homeowners insurance.